Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03546426
Title Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies (MESOVAX)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Indications

peritoneal mesothelioma

malignant mesothelioma

malignant pleural mesothelioma

Therapies

Aldesleukin + Pembrolizumab

Age Groups: adult | senior
Covered Countries

Additional content available in CKB BOOST